A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic Sclerosis

Trial Profile

A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Diffuse scleroderma
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 May 2014 New trial record
    • 02 Sep 2010
    • 15 Apr 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top